Nanoparticle delivery of cancer drugs

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 185-198

  Wang, Andrew Z ^a,b   Langer, Robert ^c   Farokhzad, Omid C ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Carolina Center for Nanotechnology Excellence   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Molecular targeted nanoparticles; Nano oncology; Nanocarriers; Nanomedicine; Nanotherapeutics

Indexed keywords

ALBUMIN; ALKALOID; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GOLD NANOPARTICLE; IDARUBICIN; IMATINIB; LIPOSOME; MITOMYCIN C; NANOPARTICLE; NAVELBINE; PACLITAXEL; POLYMER; SMALL INTERFERING RNA; TITANIUM; TRASTUZUMAB; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; HODGKIN DISEASE; HUMAN; KAPOSI SARCOMA; MONONUCLEAR PHAGOCYTE; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOFT TISSUE SARCOMA;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84855961163     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-040210-162544     Document Type: Review

References (67)

1. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387-92 (Pubitemid 17221789)
2. Gradishar WJ, Tjulandin S, Davidson N, et al. 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23:7794-803 (Pubitemid 46657376)
3. Bangham AD. 1993. Liposomes: the Babraham connection. Chem. Phys. Lipids 64:275-85 (Pubitemid 23290879)
4. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:145-60 (Pubitemid 40282557)
5. Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. 2005. Liposomal encapsulated anti-cancer drugs. Anti-Cancer Drugs 16:691-707 (Pubitemid 41104918)
6. Hawkins MJ, Soon-Shiong P, Desai N. 2008. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60:876-85
7. Desai N, Trieu V, Yao Z, et al. 2006. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12:1317-24 (Pubitemid 43342524)
8. Kim SH, Jeong JH, Chun KW, et al. 2005. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 21:8852-57 (Pubitemid 41396646)
9. Zhang L, Gu FX, Chan JM, et al. 2008. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83:761-69 (Pubitemid 351556021)
10. Farokhzad OC, Jon S, Khademhosseini A, et al. 2004. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64:7668-72 (Pubitemid 39446893)
11. Gu F, Zhang L, Teply BA, et al. 2008. Precise engineering of targeted nanoparticles by using selfassembled biointegrated block copolymers. Proc. Natl. Acad. Sci. USA 105:2586-91 (Pubitemid 351520557)
12. Rolland JP, Maynor BW, Euliss LE, et al. 2005. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127:10096-100 (Pubitemid 40995455)
13. Baker JR Jr. 2009. Dendrimer-based nanoparticles for cancer therapy. Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. pp. 708-19
14. Minelli C, Lowe SB, Stevens MM. 2010. Engineering nanocomposite materials for cancer therapy. Small (Weinheim an der Bergstrasse, Ger. ) 6:2336-57
15. Romond EH, Perez EA, Bryant J, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353:1673-84 (Pubitemid 41464706)
16. Yang JC, Haworth L, Sherry RM, et al. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349:427-34 (Pubitemid 36910021)
17. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. 2005. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23:3502-8
18. Coiffier B, Lepage E, Briere J, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-42 (Pubitemid 34438862)
19. Druker BJ, Talpaz M, Resta DJ, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:1031-37 (Pubitemid 32267972)
20. Wang AZ, Gu F, Zhang L, et al. 2008. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol. Ther. 8:1063-70
21. Service RF. 2010. Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic. Science 330:314-15
22. Jain RK, Stylianopoulos T. 2010. Delivering nanomedicine to solid tumors. Nat. Rev. 7:653-64
23. Hobbs SK, Monsky WL, Yuan F, et al. 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607-12 (Pubitemid 28207960)
24. Jang SH, Wientjes MG, Lu D, et al. 2003. Drug delivery and transport to solid tumors. Pharm. Res. 20:1337-50 (Pubitemid 37164040)
25. Maeda H, Wu J, Sawa T, et al. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:271-84 (Pubitemid 30122932)
26. Hume DA. 2006. The mononuclear phagocyte system. Curr. Opin. Immunol. 18:49-53 (Pubitemid 43049647)
27. Peracchia MT, Vauthier C, Desmaele D, et al. 1998. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 15:550-56 (Pubitemid 28214947)
28. Gratton SEA, Ropp PA, Pohlhaus PD, et al. 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105:11613-18
29. Champion JA, Walker A, Mitragotri S. 2008. Role of particle size in phagocytosis of polymeric microspheres. Pharm. Res. 25:1815-21
30. Wang M, Thanou M. 2010. Targeting nanoparticles to cancer. Pharmacol. Res. 62:90-99
31. Perrault SD, Walkey C, Jennings T, et al. 2009. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9:1909-15
32. Zauner W, Farrow NA, Haines AM R. 2001. In vitro uptake of polystyrenemicrospheres: effect of particle size, cell line and cell density. J. Control. Release 71:39-51 (Pubitemid 32195440)
33. Rejman J, Oberle V, Zuhorn IS, et al. 2004. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem. J. 377:159-69 (Pubitemid 38114443)
34. Gratton SE, Ropp PA, Pohlhaus PD, et al. 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105:11613-18
35. Young RC, Ozols RF, Myers CE. 1981. The anthracycline antineoplastic drugs. N. Engl. J. Med. 305:139-53 (Pubitemid 11073081)
36. Gaitanis A, Staal S. 2010. Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use. Methods Mol. Biol. 624:385-92
37. Singal PK, Iliskovic N. 1998. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339:900-5 (Pubitemid 28446849)
38. Keller AM, Mennel RG, Georgoulias VA, et al. 2004. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycinCplus vinblastine in womenwith taxane-refractory advanced breast cancer. J. Clin. Oncol. 22:3893-901 (Pubitemid 41079870)
39. O'Brien ME, Wigler N, Inbar M, et al. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/DOXIL) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15:440-49 (Pubitemid 38444547)
40. Gordon AN, Fleagle JT, Guthrie D, et al. 2001. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:3312-22 (Pubitemid 32642183)
41. Krown SE, Northfelt DW, Osoba D, et al. 2004. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin. Oncol. 31:36-52 (Pubitemid 40023241)
42. Harris L, Batist G, Belt R, et al. 2002. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36 (Pubitemid 34049039)
43. Batist G, Ramakrishnan G, Rao CS, et al. 2001. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19:1444-54 (Pubitemid 32202552)
44. Gill PS, Wernz J, Scadden DT, et al. 1996. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14:2353-64 (Pubitemid 26264888)
45. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al. 1993. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. 20:1-15 (Pubitemid 23239390)
46. Runowicz CD, Wiernik PH, Einzig AI, et al. 1993. Taxol in ovarian cancer. Cancer 71:1591-96 (Pubitemid 23056078)
47. Miele E, Spinelli GP, Miele E, et al. 2009. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomed. 4:99-105
48. Sparreboom A, Scripture CD, Trieu V, et al. 2005. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin. Cancer Res. 11:4136-43 (Pubitemid 40791578)
49. Kim TY, Kim DW, Chung JY, et al. 2004. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10:3708-16
50. Kim DW, Kim SY, Kim HK, et al. 2007. Multicenter phase II trial of Genexol-PM, a novel cremophorfree, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 18:2009-14
51. Lee KS, Chung HC, Im SA, et al. 2008. Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108:241-50 (Pubitemid 351311357)
52. Ravaioli A, Papi M, Pasquini E, et al. 2009. Lipoplatin monotherapy: a phase II trial of second-line treatment of metastatic non-small-cell lung cancer. J. Chemother. 21:86-90
53. Mylonakis N, Athanasiou A, Ziras N, et al. 2010. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 68:240-47
54. de Jonge MJ, Slingerland M, Loos WJ, et al. 2010. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 46:3016-21
55. Plummer R, Wilson RH, Calvert H, et al. 2011. Aphase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104:593-98
56. Dhar S, Kolishetti N, Lippard SJ, et al. 2011. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. USA 108:1850-55
57. Benesch M, Urban C. 2008. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin. Pharmacother. 9:301-9 (Pubitemid 351233737)
58. Svenson S, Wolfgang M, Hwang J, et al. 2011. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J. Control. Release 153(1):49-55
59. Batist G, Gelmon KA, Chi KN, et al. 2009. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15:692-700
60. Hamaguchi T, Doi T, Eguchi-Nakajima T, et al. 2010. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16:5058-66
61. Matsumura Y, Kataoka K. 2009. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100:572-79
62. Safavy A. 2008. Recent developments in taxane drug delivery. Curr. Drug Deliv. 5:42-54 (Pubitemid 351225633)
63. Matsumura Y, Hamaguchi T, Ura T, et al. 2004. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91:1775-81 (Pubitemid 39664964)
64. Valle JW, Armstrong A, Newman C, et al. 2011. A phase 2 study of SP1049C, doxorubicin in Pglycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29:1029-37
65. Ozpolat B, Sood AK, Lopez-Berestein G. 2010. Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 267:44-53
66. Davis ME, Zuckerman JE, Choi CH, et al. 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-70
67. Feldman EJ, Lancet JE, Kolitz JE, et al. 2011. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29:979-85